PT-141 (Bremelanotide): Discovery and Regulatory History

Introduction

The discovery of bremelanotide (PT-141) is embedded in a decades-long research program in melanocortin peptide chemistry that began with the characterization of alpha-melanocyte-stimulating hormone (alpha-MSH) and progressed through structural analog synthesis, receptor pharmacology, and ultimately clinical development by Palatin Technologies. The compound's history traverses multiple research institutions, an iterative formulation development process, and a regulatory timeline that concluded with FDA approval in 2019 as the first approved melanocortin receptor agonist for any human therapeutic indication. This article traces that history through primary literature and regulatory documents.

Discovery Period: Melanocortin Peptide Chemistry (1960s–1990s)

The foundational work underlying bremelanotide's discovery begins with the characterization of alpha-MSH, a 13-amino acid peptide derived from pro-opiomelanocortin (POMC) in the pituitary. Alpha-MSH and related melanotropin peptides were characterized as ligands for receptors expressed in pigment cells and subsequently identified in the central nervous system [1].

The melanocortin receptor family was fully delineated through molecular cloning research in the late 1980s and early 1990s. Five receptor subtypes — MC1R through MC5R — were identified and their tissue distributions characterized. MC3R and MC4R were found to be expressed predominantly in the central nervous system, with particularly dense MC4R expression in hypothalamic nuclei including the paraventricular nucleus and arcuate nucleus. The physiological significance of hypothalamic MC4R was established by Huszar and colleagues (1997), who reported that targeted disruption of the MC4R gene in mice produced hyperphagia and obesity, identifying MC4R as a critical component of hypothalamic circuits governing energy intake [2].

At the University of Arizona, Victor Hruby and colleagues developed a systematic program of synthetic melanocortin peptide analog chemistry beginning in the 1980s. Through iterative structure-activity relationship studies, the Hruby laboratory identified a core pharmacophore — the tetrapeptide segment His-Phe-Arg-Trp — that was necessary for receptor activation by alpha-MSH. Cyclization strategies were pursued to create conformationally constrained analogs with higher receptor potency and resistance to enzymatic degradation [1]. This research produced melanotan I (MT-I), a linear alpha-MSH analog, and melanotan II (MT-II), a cyclic, lactam-bridged heptapeptide analog with superpotent melanotropic activity in vitro.

Hadley and Dorr (2006) documented this research lineage and the transition toward clinical investigation, noting that MT-II was first evaluated in phase 1 clinical studies at the University of Arizona beginning in the mid-1990s [1]. Observations in those early trials directed subsequent mechanistic inquiry toward the melanocortin system's role in centrally mediated physiological responses.

Early Research: From MT-II to PT-141 (1996–2004)

Observations from early MT-II clinical studies were reported in the peer-reviewed literature and catalyzed interest in melanocortin receptor agonists as pharmacological tools in CNS-mediated research contexts [1]. Melanotan II entered additional clinical investigation to characterize these centrally mediated effects. A pilot phase 1 clinical study of melanotan II was reported by Wessells and colleagues in the Journal of Urology in 2000, in which the authors documented dose-dependent responses following MT-II administration and characterized the compound's pharmacological profile [3].

Palatin Technologies licensed melanocortin receptor agonist intellectual property and initiated its own drug development program based on the MT-II scaffold. The program produced PT-141, subsequently given the generic name bremelanotide, as a structural derivative of MT-II in which the C-terminal amide of MT-II was converted to a free hydroxyl group. This modification altered the compound's pharmacological and pharmacokinetic characteristics in ways that distinguished it from MT-II as a clinical development candidate.

An early phase 1 clinical study of PT-141 in healthy male subjects was reported by Wessells and colleagues (2000), who documented pharmacokinetic parameters and pharmacodynamic observations following subcutaneous administration [3]. A parallel early phase 1 clinical study of an intranasal formulation in healthy males and patients with erectile dysfunction was published by Diamond and colleagues (2004), reporting on safety, pharmacokinetics, and pharmacodynamic findings [4].

Diamond and colleagues (2003) also published an overview article characterizing PT-141's profile as a melanocortin agonist, drawing on both preclinical and early clinical data [5]. That publication documented that systemic administration of PT-141 in rodents was associated with increased c-Fos immunoreactivity in hypothalamic neurons, consistent with central receptor engagement, and that early clinical observations were consistent with centrally mediated responses.

Formulation Refinement: From Intranasal to Subcutaneous (2005–2011)

Comparative pharmacokinetic and safety data collected across the intranasal clinical program informed a formulation strategy decision to advance subcutaneous delivery. Inter-subject variability in intranasal bioavailability motivated the transition to subcutaneous administration, which provided more reproducible pharmacokinetics, and development focus shifted to premenopausal women with HSDD, reflecting both the regulatory landscape and the pharmacological rationale for a centrally-acting melanocortin agonist [6].

Halpern and colleagues (2017) characterized the cardiovascular profile of the subcutaneous formulation using ambulatory blood pressure monitoring, reporting mean blood pressure increases of approximately 4 mmHg lasting approximately four hours — an attenuated and more predictable signal than that associated with the intranasal compound [6]. This characterization informed the prescribing guidance in the eventual FDA-approved label.

Regulatory Milestones (2012–2019)

Following the formulation and indication focus established in the prior period, Palatin Technologies advanced bremelanotide through phase 2b and phase 3 clinical development in premenopausal women with HSDD.

A phase 2b randomized, placebo-controlled dose-finding trial published by Portman and colleagues (2017) demonstrated statistically significant differences from placebo at the 1.75 mg subcutaneous dose across multiple pre-specified psychometric endpoints, providing dose selection rationale for the phase 3 program [7].

The RECONNECT phase 3 program enrolled 1,267 premenopausal women across two parallel randomized controlled trials. Simon and colleagues (2019) reported that bremelanotide met both co-primary efficacy endpoints, with a safety profile consistent with the phase 2 characterization [8]. The 52-week open-label extension, reported by Kingsberg and colleagues (2019), identified no new safety signals over the extended observation period and provided the longest published safety dataset for the compound at the time of regulatory submission [9].

Palatin Technologies transferred commercial rights to AMAG Pharmaceuticals, which submitted NDA 210557. The FDA granted approval to bremelanotide (Vyleesi) on June 21, 2019, for the treatment of acquired, generalized HSDD in premenopausal women [10] — the first FDA authorization of any melanocortin receptor agonist and only the second approved pharmacological treatment for HSDD following flibanserin (Addyi, 2015). A broader overview of bremelanotide's chemistry and pharmacological classification is available in the PT-141 research overview.

Current Research Landscape

Following the 2019 approval, published research has continued to characterize bremelanotide's mechanism of action at the neural circuit level. Browning and colleagues (2022) published neuroimaging data characterizing the effects of MC4R agonism on brain activity patterns, representing a methodologically distinct line of inquiry from the clinical trials that supported regulatory approval [11]. The broader melanocortin receptor field has continued to attract research attention: the MC4R agonist setmelanotide received FDA approval in 2020 for specific genetic forms of obesity, reflecting the therapeutic relevance of the receptor family across multiple indications. Bremelanotide remains the only approved melanocortin receptor agonist for HSDD as of the publication date of this article. Commercial rights to Vyleesi transferred to Covis Pharma following its acquisition of AMAG Pharmaceuticals in 2020; post-marketing pharmacovigilance continues under the approved label. Research-grade PT-141 from SpartaLabs is available with batch-level Certificate of Analysis documentation.

References

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. PMID: 16412534. DOI: 10.1016/j.peptides.2005.01.029

2. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131-141. PMID: 9019399. DOI: 10.1016/s0092-8674(00)81865-6

3. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-646. PMID: 11018640. DOI: 10.1016/s0090-4295(00)00680-4

4. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. PMID: 14963471. DOI: 10.1038/sj.ijir.3901139

5. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PMID: 12851303. DOI: 10.1111/j.1749-6632.2003.tb03168.x

6. Halpern JA, Hill R, Brannigan RE. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. Ther Adv Drug Saf. 2017;8(4):125-133. PMID: 27977473. PMC: PMC5338879. DOI: 10.1177/2042098616685893

7. Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Womens Health Issues. 2017;27(3):365-372. PMC: PMC5384512. DOI: 10.1016/j.whi.2017.01.002

8. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500

9. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. PMID: 31599847. DOI: 10.1097/AOG.0000000000003506

10. US Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557. Approved June 21, 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

11. Browning KD, Bhatt DL, Maher EM, et al. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. J Sex Med. 2022;19(12):1793-1806. PMID: 36189794. PMC: PMC9525110. DOI: 10.1016/j.jsxm.2022.09.004